Adult T-cell leukemia-lymphoma

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search

Back to Top

Section editor
Bdholaria.jpg
 Bhagirathbhai Dholaria, MBBS
Vanderbilt University
Nashville, TN, USA
LinkedIn

Are you looking for a regimen, but can't find it here? It is possible that we've moved it to the historical regimens page.

5 regimens on this page
5 variants on this page
  • We have moved How I Treat articles to a dedicated page.


Guidelines

Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only.

NCCN

Untreated

CHOP-14

CHOP-14: Cyclophosphamide, Hydroxydaunorubicin (Doxorubicin), Oncovin (Vincristine), Predniso(lo)ne every 14 days
CHOP-DI: Cyclophosphamide, Hydroxydaunorubicin (Doxorubicin), Oncovin (Vincristine), Predniso(lo)ne, Dose-Intense
I-CHOP: Intensive Cyclophosphamide, Hydroxydaunorubicin (Doxorubicin), Oncovin (Vincristine), Predniso(lo)ne

Regimen

Study Dates of enrollment Evidence Comparator Comparative Efficacy Comparative Toxicity
Itoh et al. 2002 (JCOG 9505) 1995-1998 Randomized Phase 2 (E-de-esc) dose-escalated CHOP Did not meet primary endpoint of CR rate Less toxic
Tsukasaki et al. 2007 (JCOG 9801) 1998-2003 Phase 3 (C) mLSG15 Did not meet primary endpoint of OS Less toxic

Chemotherapy

Glucocorticoid therapy

Supportive therapy

  • Filgrastim (Neupogen) given once ANC decreased to less than 1000/μL and continued once per day until count increased to greater than 5000/μL

14-day cycle for 8 cycles

CNS therapy

Intrathecal triple-therapy was given during recovery phase of cycles 1, 3, and 5 after platelet count was greater than 70 × 109/L.

3 doses, total

References

  1. JCOG 9505: Itoh K, Ohtsu T, Fukuda H, Sasaki Y, Ogura M, Morishima Y, Chou T, Aikawa K, Uike N, Mizorogi F, Ohno T, Ikeda S, Sai T, Taniwaki M, Kawano F, Niimi M, Hotta T, Shimoyama M, Tobinai K; JCOG. Randomized phase II study of biweekly CHOP and dose-escalated CHOP with prophylactic use of lenograstim (glycosylated G-CSF) in aggressive non-Hodgkin's lymphoma: Japan Clinical Oncology Group Study 9505. Ann Oncol. 2002 Sep;13(9):1347-55. link to original article PubMed
  2. JCOG 9801: Tsukasaki K, Utsunomiya A, Fukuda H, Shibata T, Fukushima T, Takatsuka Y, Ikeda S, Masuda M, Nagoshi H, Ueda R, Tamura K, Sano M, Momita S, Yamaguchi K, Kawano F, Hanada S, Tobinai K, Shimoyama M, Hotta T, Tomonaga M; JCOG. VCAP-AMP-VECP compared with biweekly CHOP for adult T-cell leukemia-lymphoma: Japan Clinical Oncology Group Study JCOG9801. J Clin Oncol. 2007 Dec 1;25(34):5458-64. Epub 2007 Oct 29. link to original article contains dosing details in manuscript PubMed NCT00145002

mLSG15

Regimen

Study Dates of enrollment Evidence Comparator Comparative Efficacy
Tsukasaki et al. 2007 (JCOG 9801) 1998-2003 Phase 3 (E-esc) CHOP-14 Did not meet primary endpoint of OS
Ishida et al. 2015 (Kyowa 0761-003) 2010-2011 Randomized Phase 2 (C) mLSG15 & Mogamulizumab Did not meet primary endpoint of CR rate

Note: Ranimustine is not available in the United States and is approved only in Japan.

Chemotherapy

Glucocorticoid therapy

28-day cycle for 6 cycles

CNS therapy, prophylaxis

Given after cycles 1, 3, and 5 after platelets greater than 70 × 109/L and within 2 days before the next cycle

References

  1. JCOG 9801: Tsukasaki K, Utsunomiya A, Fukuda H, Shibata T, Fukushima T, Takatsuka Y, Ikeda S, Masuda M, Nagoshi H, Ueda R, Tamura K, Sano M, Momita S, Yamaguchi K, Kawano F, Hanada S, Tobinai K, Shimoyama M, Hotta T, Tomonaga M; JCOG. VCAP-AMP-VECP compared with biweekly CHOP for adult T-cell leukemia-lymphoma: Japan Clinical Oncology Group Study JCOG9801. J Clin Oncol. 2007 Dec 1;25(34):5458-64. Epub 2007 Oct 29. link to original article contains dosing details in manuscript PubMed NCT00145002
  2. Kyowa 0761-003: Ishida T, Jo T, Takemoto S, Suzushima H, Uozumi K, Yamamoto K, Uike N, Saburi Y, Nosaka K, Utsunomiya A, Tobinai K, Fujiwara H, Ishitsuka K, Yoshida S, Taira N, Moriuchi Y, Imada K, Miyamoto T, Akinaga S, Tomonaga M, Ueda R. Dose-intensified chemotherapy alone or in combination with mogamulizumab in newly diagnosed aggressive adult T-cell leukaemia-lymphoma: a randomized phase II study. Br J Haematol. 2015 Jun;169(5):672-82. Epub 2015 Mar 2. link to original article link to PMC article PubMed NCT01173887

Relapsed or refractory

Alemtuzumab monotherapy

Regimen

Study Dates of enrollment Evidence
Sharma et al. 2016 2004-2009 Phase 2

Note: Scheduling is timed to start on a Monday.

Targeted therapy

  • Alemtuzumab (Campath) as follows:
    • Cycle 1: 3 mg IV once on day 1, then 10 mg IV once on day 2, then 30 mg IV once per day on days 3 & 5
    • Cycles 2 to 12: 30 mg IV once per day on days 1, 3, 5 or 2, 4, 6 (three times per week)

Supportive therapy

7-day cycle for up to 12 cycles

References

  1. Sharma K, Janik JE, O'Mahony D, Stewart D, Pittaluga S, Stetler-Stevenson M, Jaffe ES, Raffeld M, Fleisher TA, Lee CC, Steinberg SM, Waldmann TA, Morris JC. Phase II study of alemtuzumab (CAMPATH-1) in patients with HTLV-1-associated adult T-cell leukemia/lymphoma. Clin Cancer Res. 2017 Jan 1;23(1):35-42. Epub 2016 Aug 2. link to original article link to PMC article contains dosing details in manuscript PubMed

Lenalidomide monotherapy

Regimen

Study Dates of enrollment Evidence Efficacy
Ishida et al. 2016 (ATLL-002) 2012-2014 Phase 2 ORR: 42% (95% CI 23-63)

Targeted therapy

Continued indefinitely

References

  1. ATLL-002: Ishida T, Fujiwara H, Nosaka K, Taira N, Abe Y, Imaizumi Y, Moriuchi Y, Jo T, Ishizawa K, Tobinai K, Tsukasaki K, Ito S, Yoshimitsu M, Otsuka M, Ogura M, Midorikawa S, Ruiz W, Ohtsu T. Multicenter phase II study of lenalidomide in relapsed or recurrent adult T-cell leukemia/lymphoma: ATLL-002. J Clin Oncol. 2016 Dec;34(34):4086-4093. Epub 2016 Sep 30. link to original article contains dosing details in manuscript PubMed NCT01724177

Valemetostat monotherapy

Regimen

Study Dates of enrollment Evidence
Izutsu et al. 2022 (DS3201-A-J201) 2019-11 to 2020-10 Phase 2 (RT)

Targeted therapy

  • Valemetostat (Ezharmia) 200 mg PO once per day on days 1 to 28, taken at least 2 hours before or at least 1 hour after a meal

28-day cycles

References

  1. DS3201-A-J201: Izutsu K, Makita S, Nosaka K, Yoshimitsu M, Utsunomiya A, Kusumoto S, Morishima S, Tsukasaki K, Kawamata T, Ono T, Rai S, Katsuya H, Ishikawa J, Yamada H, Kato K, Tachibana M, Kakurai Y, Adachi N, Tobinai K, Yonekura K, Ishitsuka K. An open-label, single-arm phase 2 trial of valemetostat for relapsed or refractory adult T-cell leukemia/lymphoma. Blood. 2023 Mar 9;141(10):1159-1168. Epub 2022 Sep 27. link to original article link to PMC article contains dosing details in manuscript PubMed NCT04102150
Retrieved from "https://hemonc.org/w/index.php?title=Adult_T-cell_leukemia-lymphoma&oldid=83155"